Interestingly, patients with tumours that do not overexpress the EGFR but overexpress cortactin had a 5-year overall survival of 22%, similar to patients with tumours that overexpress both EGFR and cortactin (Figure 3D). The gene discussed is EGFR; the disease is neoplasm.